-
公开(公告)号：WO2019157131A1
公开(公告)日：2019-08-15
申请号：PCT/US2019/016976
申请日：2019-02-07
Applicant: DANA-FARBER CANCER INSTITUTE, INC.
Inventor： WALENSKY, Loren D. , MOURTADA, Rida , HERCE, Henry D.
CPC classification number: C07K14/00 , A61K38/00 , A61K39/395 , C07K7/06 , C07K7/56 , C07K14/001 , C07K14/003 , C07K16/00 , C07K2319/10
Abstract: The disclosure relates to cell-permeable stabilized peptide modules and methods of use for e.g., cellular delivery of cargoes.
-
公开(公告)号：WO2019150309A1
公开(公告)日：2019-08-08
申请号：PCT/IB2019/050799
申请日：2019-01-31
Applicant: HAMMACK, Scott , LAFFITTE, Bryan , PATAPOUTIAN, Ardem , XU, Jie
Inventor： HAMMACK, Scott , LAFFITTE, Bryan , PATAPOUTIAN, Ardem , XU, Jie
IPC: A61K38/00 , A61K39/395 , A61K31/713 , A61P1/16 , A61P9/00
CPC classification number: A61K31/713 , A61K38/00 , A61K39/3955 , A61P1/16 , A61P9/00
Abstract: This disclosure provides novel compositions, methods, and therapeutic uses related to modulators of a GPR68 gene product. Some embodiments disclosed herein provide methods of modulating flow-mediated dilation (FMD) response or flow-mediated outward remodeling (FMR) of small-diameter arteries, or reducing systemic vascular resistance (SVR) in a subject in need thereof comprising administering a modulator of a GPR68 gene product to the subject. Some embodiments disclosed herein provide methods of treating a cardiovascular disease in a subject in need thereof comprising administering a pharmaceutical composition comprising a modulator of a GPR68 gene product to the subject.
-
公开(公告)号：WO2019117976A1
公开(公告)日：2019-06-20
申请号：PCT/US2017/066893
申请日：2017-12-17
Inventor： SCHNEIDER, Joel , WALSH, Scott , MILLER, Stephen , YAMADA, Yuji , DURUM, Scott , ANDREWS, Caroline , LI, Wenqing , HIXON, Julie , TAU, Stephen
CPC classification number: C07K14/001 , A61K38/00 , A61L27/22 , A61L27/52 , A61L2400/06 , C07K7/08 , C07K14/705 , C07K2319/00 , C08L2203/02
Abstract: This disclosure provides novel anionic amphiphilic β-hairpin peptides that self-assemble under appropriate conditions to form a reversible gel-sol hydrogel that can be used, for example, to readily deliver protein therapeutics and cells by injection to a target location in a subject.
-
公开(公告)号：WO2019112941A1
公开(公告)日：2019-06-13
申请号：PCT/US2018/063581
申请日：2018-12-03
Inventor： YOSEPH, Rami , LU, Yong-Chen , CAFRI, Gal , ROSENBERG, Steven A.
IPC: A61K39/00 , C07K14/47 , A61K38/17 , C07K14/725
CPC classification number: A61K39/001164 , A61K38/00 , C07K14/7051 , C07K14/70539 , C07K14/82
Abstract: Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a mutated RAS amino acid sequence presented by a human leukocyte antigen (HLA) Class I molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
-
公开(公告)号：WO2019101308A1
公开(公告)日：2019-05-31
申请号：PCT/EP2017/080117
申请日：2017-11-22
Applicant: MERZ PHARMA GMBH & CO. KGAA
Inventor： FREVERT, Jürgen , HOFMANN, Fred , JURK, Marcel , LÓPEZ DE LA PAZ, Manuela , SCHEPS, Daniel
CPC classification number: C12N9/52 , A61K8/64 , A61K8/99 , A61K38/00 , A61Q19/08 , C07K14/33 , C07K2319/31 , C07K2319/50 , C12Y304/24069
Abstract: This invention relates to novel recombinant clostridial neurotoxins exhibiting an increased duration of effect and to methods for the manufacture of such recombinant clostridial neurotoxins. These novel recombinant clostridial neurotoxins comprise at least one domain wherein said domain comprises an amino acid sequence consisting of at least 50 amino acid residues, wherein said amino acid sequence consists of at least one proline and at least one alanine residue. The invention relates also to novel recombinant clostridial neurotoxins comprising at least one domain wherein said domain comprises an amino acid sequence consisting of at least 50 amino acid residues, wherein said domain comprises a plurality of specific amino acid repeats consisting of proline, alanine and tyrosine residues, or proline, alanine and glutamine residues, or proline, alanine and threonine residues.
-
Patent Agency Ranking
公开(公告)号：WO2019087108A1
公开(公告)日：2019-05-09
申请号：PCT/IB2018/058555
申请日：2018-10-31
Applicant: PROBIOMED S.A. DE C.V.
Inventor： ESPINOSA DE LA GARZA, Carlos Eduardo , MUCIÑO ALCÁNTARA, María de Lourdes , CAMPOS GARCÍA, Victor Raúl , PIÑA LARA, Nelly , MIRANDA HERNÁNDEZ, Mariana Patricia , TIERRABLANCA SÁNCHEZ, Lilia , SALAZAR FLORES, Rodolfo Daniel , SALAZAR CEBALLOS, Rodolfo , FLORES ORTÍZ, Luis Francisco , PÉREZ RAMÍREZ, Néstor Octavio
IPC: A61K38/00 , A61K39/395 , A61K47/00 , C07K14/525 , C07K16/00 , A61P19/02
CPC classification number: A61K38/00 , A61K39/395 , A61K47/00 , A61P19/02 , C07K14/525 , C07K16/00
Abstract: La presente invención describe una nueva formulación líquida para Etanercept, una proteína de fusión recombinante TNFR:Fc dirigida contra el TNFα en alta concentración (20 a 100 mg/mL), en presencia de una solución amortiguadora de pH de histidina o succinato, que mantienen un pH en el intervalo de 5.8 a 6.8, adicionadas con polisorbato, sacarosa o trehalosa, y manitol utilizado como agente tonificante. Esta formulación hace uso de un menor número de excipientes que las formulaciones descritas en el estado de la técnica y en una combinación nunca antes utilizada. Además, presenta un porcentaje de impurezas disminuido y una termoestabilidad incrementada a la formula líquida de Enbrel®, mientras se mantiene la identidad fisicoquímica y potencia biológica de Etanercept.
-
公开(公告)号：WO2019067887A1
公开(公告)日：2019-04-04
申请号：PCT/US2018/053405
申请日：2018-09-28
Applicant: SPYRYX BIOSCIENCES, INC.
Inventor： SCOTT, David Wayne , SESMA, Juliana I. , WALKER, Paul Matthew
Abstract: The disclosure relates to epithelial sodium channel (ENaC) inhibitor compounds and peptides and uses thereof, e.g. , in the treatment of a disorder related to sodium channel, such as, for example, cystic fibrosis, idiopathic pulmonary fibrosis, or chronic obstructive pulmonary disease.
-
公开(公告)号：WO2019046698A1
公开(公告)日：2019-03-07
申请号：PCT/US2018/049055
申请日：2018-08-31
Applicant: THOMAS JEFFERSON UNIVERSITY , BOUND THERAPEUTICS, LLC
Inventor： WICKSTROM, Eric , JIN, Yuan-Yuan
IPC: A61K31/712 , A61K31/7125 , A61K38/07 , A61P29/00 , A61P35/00 , A61P37/00
CPC classification number: A61P29/00 , A61K38/00 , A61K47/64 , A61P35/00 , A61P37/00 , C07K14/47 , C12N15/00 , C12N15/113 , C12N2310/11 , C12N2310/3231 , C12N2310/341 , C12N2310/3513
Abstract: The present invention provides compositions and methods of making and using novel MYC mRNA antisense inhibitors. In a particular embodiment, the invention features compositions and methods useful for the treatment of a condition (e.g., cancer).
-
公开(公告)号：WO2019040507A1
公开(公告)日：2019-02-28
申请号：PCT/US2018/047345
申请日：2018-08-21
Applicant: PREVAIL THERAPEUTICS, INC. , ASHIYA, Mona
Inventor： ASHIYA, Mona
CPC classification number: C12N9/2462 , A61K9/0019 , A61K9/0085 , A61K38/00 , A61K47/60 , C07K2319/35 , C12Y302/01017
Abstract: Provided herein are lysosomal enzymes comprising modifications that increase stability, pharmaceutical compositions thereof, and methods of using such compounds for the treatment of disorders associated with lysosomal enzyme deficiency.
-
公开(公告)号：WO2019027224A2
公开(公告)日：2019-02-07
申请号：PCT/KR2018/008680
申请日：2018-07-31
Applicant: 서울대학교 산학협력단
Abstract: 본 발명은 결핵균의 독소-항독소 체계를 표적으로 하는 펩타이드 및 이의 용도에 관한 것으로, 구체적으로 본 발명의 항생 펩타이드는 독소의 활성부위에는 영향을 미치지 않으면서 결핵균의 독소-항독소 복합체의 형성을 방해함으로써 분리된 독소에 의한 결핵균의 사멸을 유도한다. 따라서, 상기 항생 펩타이드는 결핵균에 대한 항생용 조성물로서 유용하게 사용될 수 있다.
-
-
-
-
-
-
-
-
-
Search Results
37913
records
(took 0.029 seconds)
